129 related articles for article (PubMed ID: 28203164)
21. GATA3 and MYB Expression in Cutaneous Adnexal Neoplasms.
Pardal J; Sundram U; Selim MA; Hoang MP
Am J Dermatopathol; 2017 Apr; 39(4):279-286. PubMed ID: 28323779
[TBL] [Abstract][Full Text] [Related]
22. RANK and RANK ligand expression in primary human osteosarcoma.
Branstetter D; Rohrbach K; Huang LY; Soriano R; Tometsko M; Blake M; Jacob AP; Dougall WC
J Bone Oncol; 2015 Sep; 4(3):59-68. PubMed ID: 27556008
[TBL] [Abstract][Full Text] [Related]
23. Definitive Chemoradiotherapy for Advanced Pulmonary Sarcomatoid Carcinoma.
Takeda K; Matsushita H; Kubozono M; Tanabe T; Ishikawa Y; Yamamoto T; Kozumi M; Takahashi N; Katagiri Y; Tasaka S; Fukui K; Takeda K; Fujishima F; Ichinose M; Jingu K
Intern Med; 2016; 55(22):3325-3330. PubMed ID: 27853077
[TBL] [Abstract][Full Text] [Related]
24. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Liu Q; Zhang JH; Deng JY; Ai TS; Zhu HT; Badakhshi H; Zhao KL
Int J Clin Oncol; 2018 Jun; 23(3):458-465. PubMed ID: 29435872
[TBL] [Abstract][Full Text] [Related]
27. Malignant Sarcomatous Transformation of Benign Giant Cell Tumor of Bone after Treatment with Denosumab Therapy: A Literature Review of Reported Cases.
Alaqaili SI; Abduljabbar AM; Altaho AJ; Khan AA; Alherabi JA
Cureus; 2018 Dec; 10(12):e3792. PubMed ID: 30868006
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous scrotal metastasis: origins and clinical characteristics of visceral malignancies that metastasize to the scrotum.
Hoyt BS; Cohen PR
Int J Dermatol; 2013 Apr; 52(4):398-403; quiz 403-5. PubMed ID: 23331276
[TBL] [Abstract][Full Text] [Related]
29. Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female - a case report and literature review.
Bardakhchyan S; Kager L; Danielyan S; Avagyan A; Karamyan N; Vardevanyan H; Mkhitaryan S; Papyan R; Zohrabyan D; Safaryan L; Sargsyan L; Harutyunyan L; Hakobyan L; Iskanyan S; Tamamyan G
Ital J Pediatr; 2017 Mar; 43(1):32. PubMed ID: 28356124
[TBL] [Abstract][Full Text] [Related]
30. 'Salvage Treatment' of Aggressive Giant Cell Tumor of Bones with Denosumab.
Vaishya R; Agarwal AK; Vijay V
Cureus; 2015 Jul; 7(7):e291. PubMed ID: 26251767
[TBL] [Abstract][Full Text] [Related]
31. A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab.
Mak IW; Evaniew N; Popovic S; Tozer R; Ghert M
J Bone Joint Surg Am; 2014 Aug; 96(15):e127. PubMed ID: 25100780
[TBL] [Abstract][Full Text] [Related]
32. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
[TBL] [Abstract][Full Text] [Related]
33. Giant cell tumour of bone in the denosumab era.
van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
[TBL] [Abstract][Full Text] [Related]
35. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant and Adjuvant Treatment with Denosumab in Aggressive Giant-cell Tumor of Bone in the Proximal Fibula: a Case Report.
Marinova VV; Slavchev SA; Patrikov KD; Tsenova PM; Georgiev GP
Folia Med (Plovdiv); 2018 Dec; 60(4):637-640. PubMed ID: 31188771
[TBL] [Abstract][Full Text] [Related]
37. [Anti-RANKL antibody].
Omiya T; Tanaka S
Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
[TBL] [Abstract][Full Text] [Related]
38. Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.
Rolfo C; Raez LE; Russo A; Reguart N; Campelo RG; Bronte G; Papadimitriou K; Silvestris F
Expert Opin Biol Ther; 2014 Jan; 14(1):15-26. PubMed ID: 24161019
[TBL] [Abstract][Full Text] [Related]
39. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
40. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
